EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

A Phase 2, Multi‐Center, Randomized, Double‐Blind, Parallel‐Group Trial to Evaluate the Efficacy and Safety of CKD‐495 in Patients With Acute and Chronic Gastritis

Su Hyun Park iD, Oh Young Lee iD, Yong Chan Lee, Kyung Sik Park, Jong Jae Park, Moo In Park, Geun Am Song, Dong Ho Lee, Hyunsoo Jung, Sung Kook Kim, Tae Nyeun Kim, Suck-Chei Choi und 6 weitere

Canadian Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1155/cjgh/2702089 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, 2025. Verfasst von Su Hyun Park und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Anti-Ulcer Agents, Gastritis, Plant Extracts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CKD‐495 is a newly developed drug extracted from Cinnamomum cassia Presl. This phase II study assessed the clinical benefits of CKD‐495 in the treatment of acute and chronic gastritis. This study randomly assigned 250 patients with endoscopically‐proven gastric mucosal erosion to five groups. The groups received either 75 mg or 150 mg of CKD‐495, 100 mg of rebamipide, 60 mg of Artemisiae argyi folium 95% ethanol ext. (20 ⟶ 1) (Stillen; Dong‐A ST Co., Ltd., Seoul, Korea), or placebo for 2 weeks, respectively. The primary endpoint was the erosion improvement rate, and the secondary endpoints were erosion cure rates, improvement rates of gastrointestinal symptoms, edema, redness, and hemorrhage. Drug‐related adverse events were evaluated. The endoscopic erosion improvement rate was significantly higher in the 75 mg CKD‐495 group than in the other groups in both the full analysis set (73% vs. 41%, 45%, 52%, 48% for the 75 mg CKD‐495, 150 mg CKD‐495, placebo, 60 mg Stillen, and 100 mg rebamipide groups, respectively) and the per‐protocol set (PPS) (75% vs. 37%, 45%, 51%, 50%). The cure rate of gastric erosion was significantly higher in the 75 mg CKD‐495 group than in the other groups. The improvement rates of hemorrhage erosion were significantly higher in the 150‐mg CKD‐495 group. No significant differences were observed in the safety profiles. No serious adverse events or drug reactions were observed. These results demonstrate that 75 mg of CKD‐495 has excellent efficacy for the treatment of endoscopic and symptomatic improvements for acute and chronic gastritis. Trial Registration: ClinicalTrials.gov identifier: NCT03437785

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Ulcer AgentsGastritisPlant ExtractsAdultAgedFemaleHumansMaleMiddle AgedAcute DiseaseAlanineChronic DiseaseDouble-Blind MethodGastric MucosaQuinolonesTreatment Outcome

Substanzen

AlanineAnti-Ulcer AgentsPlant ExtractsQuinolonesrebamipide

Autor:innen und Institutionen

  • Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Keimyung University College of Medicine, Daegu, Republic of Korea.
  • Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, Kosin University College of Medicine, Busan, Republic of Korea.
  • Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea.

ORCID-Profile: Su Hyun Park, Oh Young Lee

Zitieren

APA

Park, S. H., Lee, O. Y., Lee, Y. C., Park, K. S., Park, J. J., Park, M. I., Song, G. A., Lee, D. H., Jung, H., Kim, S. K., Kim, T. N., Choi, S. C., Jee, S. R., Rew, J. S., Lee, S. T., Choi, E. K., Baik, G. H., & Park, S. J. (2025). A Phase 2, Multi‐Center, Randomized, Double‐Blind, Parallel‐Group Trial to Evaluate the Efficacy and Safety of CKD‐495 in Patients With Acute and Chronic Gastritis. Canadian Journal of Gastroenterology and Hepatology. https://doi.org/10.1155/cjgh/2702089

Vancouver

Park SH, Lee OY, Lee YC, Park KS, Park JJ, Park MI, et al. A Phase 2, Multi‐Center, Randomized, Double‐Blind, Parallel‐Group Trial to Evaluate the Efficacy and Safety of CKD‐495 in Patients With Acute and Chronic Gastritis. Canadian Journal of Gastroenterology and Hepatology. 2025. doi:10.1155/cjgh/2702089

BibTeX
@article{Park2025,
  author = {Park, Su Hyun and Lee, Oh Young and Lee, Yong Chan and Park, Kyung Sik and Park, Jong Jae and Park, Moo In and Song, Geun Am and Lee, Dong Ho and Jung, Hyunsoo and Kim, Sung Kook and Kim, Tae Nyeun and Choi, Suck-Chei and Jee, Sam Ryong and Rew, Jong Sun and Lee, Soo Teik and Choi, Eun Kwang and Baik, Gwang Ho and Park, Shin Jung},
  title = {A Phase 2, Multi‐Center, Randomized, Double‐Blind, Parallel‐Group Trial to Evaluate the Efficacy and Safety of CKD‐495 in Patients With Acute and Chronic Gastritis},
  journal = {Canadian Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1155/cjgh/2702089}
}
Kostenlos starten →